The PANSS is currently the most established scale in patients with schizophrenia. For example in the high impact journal "Schizophrenia Bulletin" Kay's publication on the Positive and Negative ...
AbbVie’s emraclidine trials for schizophrenia failed to meet PANSS score improvement at week 6. Despite this setback, analyst says the Cerevel acquisition still holds promise, with other treatments.
Recently approved xanomeline and trospium chloride (Cobenfy) demonstrated long-term efficacy and safety in patients with schizophrenia, long-term results from the phase III EMERGENT-4 trial showed.
APD = Antipsychotic background drug; PANSS = Positive and Negative Syndrome Scale; PSP = Personal and Social Performance Scale; CGI-S = Clinical Global Impressions Severity Scale; mITT = modified ...
A notable difference in effect was seen among patients who received risperidone as their background antipsychotic vs those on non-risperidone antipsychotics. Topline results were announced from a ...
Background: The PANSS (Positive and Negative Syndrome Scale) is one of the most important rating instruments for patients with schizophrenia. Nevertheless, there is a long and ongoing debate in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback